# An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea

> **NCT07232537** · — · RECRUITING · sponsor: **Bayer** · enrollment: 500 (estimated)

## Conditions studied

- Chronic Kidney Disease
- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Kerendia (Finerenone, BAY94-8862)

## Key facts

- **NCT ID:** NCT07232537
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-20
- **Primary completion:** 2027-09-30
- **Final completion:** 2028-01-28
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07232537

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07232537, "An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea". Retrieved via AI Analytics 2026-08-09 from https://api.ai-analytics.org/clinical/NCT07232537. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*